Based on the National Comprehensive Cancer Network (NCCN) guidelines, the recommended imatinib dosage for CEL patients with the FIP1L1-PDGFRa fusion gene is 100- 400mg daily. The gene discussed is PDGFRA; the disease is Chronic Eosinophilic Leukemia, Not Otherwise Specified.